Dataset Information

Toward Oral Supplementation of Diamine Oxidase for the Treatment of Histamine Intolerance.

ABSTRACT: A new diamine oxidase (DAO-1) was discovered recently in the yeast Yarrowia lipolytica PO1f and investigated for its histamine degradation capability under simulated intestinal conditions. DAO-1 was formulated together with catalase as a sucrose-based tablet. The latter (9 × 7 mm; 400 mg) contained 690 nkat of DAO-1 activity, which was obtained from a bioreactor cultivation of a genetically modified Y. lipolytica with optimized downstream processing. The DAO-1 tablet was tested in a histamine bioconversion experiment under simulated intestinal conditions in the presence of food constituents, whereby about 30% of the histamine was degraded in 90 min. This amount might already be sufficient to help people with histamine intolerance. Furthermore, it was found that the stability of DAO-1 in a simulated intestinal fluid is influenced distinctively by the presence of a food matrix, indicating that the amount and type of food consumed affect the oral supplementation with DAO. This study showed for the first time that a microbial DAO could have the potential for the treatment of histamine intolerance by oral supplementation.

SUBMITTER: Kettner L

PROVIDER: S-EPMC9268349 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Toward Oral Supplementation of Diamine Oxidase for the Treatment of Histamine Intolerance.

Kettner Lucas L Seitl Ines I Fischer Lutz L

Nutrients 20220624 13

A new diamine oxidase (DAO-1) was discovered recently in the yeast <i>Yarrowia lipolytica</i> PO1f and investigated for its histamine degradation capability under simulated intestinal conditions. DAO-1 was formulated together with catalase as a sucrose-based tablet. The latter (9 × 7 mm; 400 mg) contained 690 nkat of DAO-1 activity, which was obtained from a bioreactor cultivation of a genetically modified <i>Y. lipolytica</i> with optimized downstream processing. The DAO-1 tablet was tested in ...[more]

PMID: 35807806

Similar Datasets

Project description:Histamine Intolerance (HIT) is a multifaceted pseudoallergic disorder possibly due to defective histamine metabolism. Diamine oxidase (DAO) contributes to histamine degradation and can be measured in the serum. The role of DAO measurement in the diagnostic work-up of HIT still remains unclear, and conflicting results have been reported in the literature. Therefore, we aimed to evaluate the possible clinical usefulness and consistency of DAO value ranges as provided by the assay manufacturer and verify whether they could predict the response to treatment. We retrospectively analyzed 192 outpatients with HIT symptoms and measured serum DAO values at baseline. Patients were prescribed either with low-histamine diet and/or enzymatic supplementation according to symptom severity and re-evaluated six to eight months later. Patients were stratified into three groups according to DAO levels: <3 U/mL, 3-10 U/mL, and >10 U/mL. HIT severity was assessed on a scale of 1 to 5 before and after treatment. A total of 146 patients completed the study. Gastrointestinal and cutaneous symptoms, often associated with headache, were more frequent in subjects with DAO < 10 U/mL. Symptom severity and DAO ranges were correlated. Patients with intermediate DAO levels (3-10 U/mL) showed a more complex clinical phenotype but also a more significant improvement in symptom severity (score reduction 50%, interquartile range (IQR) = 33-60%) when compared to patients with low DAO (40%, IQR = 20-60%; p = 0.045) or high DAO (33%, IQR = 0-50%; p < 0.001). Complex clinical phenotypes were also more frequent in patients with intermediate DAO levels. HIT is characterized by typical symptoms and low levels of DAO activity. Symptom severity was associated with the degree of DAO deficiency. Patients with DAO values between 3 and 10 U/mL show the best response to treatment (low-histamine diet and/or DAO supplementation). DAO value could arguably be considered as a predictor of clinical response to treatment. Prospective studies are needed to confirm these data.

Dataset Information

Toward Oral Supplementation of Diamine Oxidase for the Treatment of Histamine Intolerance.

Publications

Toward Oral Supplementation of Diamine Oxidase for the Treatment of Histamine Intolerance.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets